|
LAB RESULTS
|
PAGE |
|
1 |
CALCIUM - HYPERCALCAEMIA |
||
2 |
CALCIUM - HYPOCALCAEMIA |
||
3 |
SODIUM - HYPERNATRAEMIA |
||
4 |
SODIUM - HYPONATRAEMIA |
||
5 |
PLATELETS - RAISED |
||
6 |
LIVER FUNCTION TESTS |
||
7 |
IRON STUDIES |
|
DERMATOLOGY
|
PAGE |
|
1 |
Acne |
||
2 |
Psoriasis |
|
DIABETES
|
PAGE |
|
1 |
Identifying People at High Risk of Type 2 Diabetes |
||
2 |
The Diagnosis and Classification of Diabetes in Primary Care |
||
3 |
Type 2 Diabetes Cardiovascular Renal Metabolic Review Checklist |
||
4 |
What Next After Metformin? Part 1:Metformin, Sulfonylureas, Thiazolidinediones, and DPP-4 Inhibitors
|
||
5 |
What Next After Metformin? Part 2: SGLT2 Inhibitors, GLP-1 RAs, and GLP-1/GIP RAs
|
||
6 |
Extra-Glycaemic Indications of SGLT2 Inhibitors |
||
7 |
Use of Liraglutide, Semaglutide, and Tirzepatide for Adults Living With Overweight and Obesity
|
||
8 |
Hyperglycaemia - Pharmacological Managementin People Living with Type 2 Diabetes and Chronic Kidney Disease
|
|
WEIGHT LOSS
|
PAGE |
|
1 |
Weight loss injections - Use of Liraglutide, Semaglutide, and Tirzepatidefor Adults Living With Overweight and Obesity
|
|
KIDNEYS
|
PAGE |
|
1 |
Chronic Kidney Disease in Primary Care:Identification
|
||
2 |
Chronic Kidney Disease in Primary Care:Holistic Management of
|
|
LIVER
|
PAGE |
|
1 |
MASLD and MASH: Identification and Management |
|
THYROID
|
PAGE |
|
1 |
Subclinical hypothyroidism |
|
Prescribing
|
PAGE |
|
1 |
Prescribing Pearls |
|
Lipids
|
PAGE |
|
1 |
Lipid Management for the Primary and Secondary Preventionof Cardiovascular Disease
|
|
CARDIOVASCULAR
|
PAGE |
|
1 |
Heart Failure with Reduced Ejection Fraction |
||
2 |
Heart Failure with Preserved Ejection Fraction |
||
4 |
Lifestyle Changes for Managing Hypertension
|
||
5 |
DOAC Dosing for Stroke Prevention in People with Nonvalvular AF and Renal Impairment
|